Research programme: farnesyl transferase inhibitors - Merck
Alternative Names: Farnesyl transferase inhibitors research programme - MerckLatest Information Update: 12 Feb 2008
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Feb 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 May 2000 New profile
- 04 May 2000 Preclinical development for Cancer in USA (Unknown route)